Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
The FSHD Society's September 23 podcast gives voice to thousands fighting FSH muscular dystrophy
The livestream will feature patients, families and allies who are "walking and rolling" across the U.S. and Canada to raise awareness and funds for the debilitating condition RANDOLPH, Mass., Sept. 22, 2023 /PRNewswire-PRWeb/ -- The FSHD Society announced that this Saturday, September 23,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 22, 2023 Category: Pharmaceuticals Tags: FVT Source Type: news
Filmmakers to champion the FSHD Society's Los Angeles Walk & amp; Roll to Cure FSH muscular dystrophy
For the team behind the forthcoming movie, Good Bad Things, it's personal LOS ANGELES, Sept. 14, 2023 /PRNewswire-PRWeb/ -- The team behind the forthcoming movie, "Good Bad Things," will be coming out this September 17th to support to the FSHD Society's sixth annual Walk & Roll to Cure... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 14, 2023 Category: Pharmaceuticals Source Type: news
Good News Tuesday: Entrada Therapeutics supports initiatives to help those with Duchenne Muscular Dystrophy
Entrada Therapeutics Inc. a biopharmaceutical company aiming to transform the lives of patients through its new class of medicines, has announced recipients of its inaugural Entrada DREAMS Grant Program. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 12, 2023 Category: Pharmaceuticals Source Type: news
The FSHD Society Celebrates Fulcrum's Milestone in the Fight Against FSHD
Fulcrum Therapeutics has announced successful completion of patient enrollment in REACH Phase 3 trial RANDOLPH, Mass., Sept. 8, 2023 /PRNewswire-PRWeb/ -- The FSHD Society, a leading advocate and partner in the quest to find treatments for Facioscapulohumeral Muscular Dystrophy (FSHD), is... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 8, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
European Commission approves Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment2,3Evrysdi is the only non-invasive SMA therapy and is approved in 100 countries with more than 11,000 patients treated globallyBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the extension of the Evrysdi ® (risdiplam) European Union (EU) marketing ...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment2,3Evrysdi is the only non-invasive SMA therapy and is approved in 100 countries with more than 11,000 patients treated globallyBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the extension of the Evrysdi ® (risdiplam) European Union (EU) marketing ...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Curi Bio lands over $4.4M in NIH grants for two projects
The Seattle-based biotech company is working on projects in Duchenne muscular dystrophy and Botox, which can be used to treat afflictions such as muscle spasms and chronic pain. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 24, 2023 Category: Pharmaceuticals Authors: Rick Morgan Source Type: news
FDA-approved gene therapy invented at Nationwide Children's carries a $3.2M price tag. Here's why.
On Wednesday, a 5-year-old boy in Washington, D.C., received the first infusion with FDA-approved Elevidys, a gene therapy invented at Nationwide Children's Hospital for Duchenne muscular dystrophy, which usually kills by age 30. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 4, 2023 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news
FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives
'How long before my heart fails?' Tanner Edwards asked his mom after losing access to a FibroGen drug he's taken for six years for Duchenne muscular dystrophy. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 31, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Media News - July 21, 2023 Category: Pharmaceuticals Source Type: news
CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Investor Update - July 21, 2023 Category: Pharmaceuticals Source Type: news
Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs
The company last month promised cost reductions after its drug pamrevlumab failed two late-stage clinical trials, in the lung-scarring disease idiopathic pulmonary fibrosis and Duchenne muscular dystrophy. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 19, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news
